Exelixis, Inc.
NASDAQ:EXEL
Overview | Financials
Company Name | Exelixis, Inc. |
Symbol | EXEL |
Currency | USD |
Price | 36.2 |
Market Cap | 10,337,959,800 |
Dividend Yield | 0% |
52-week-range | 20.02 - 37.59 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Michael M. Morrissey Ph.D. |
Website | https://www.exelixis.com |
An error occurred while fetching data.
About Exelixis, Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD